Although the HER2-enriched subtype has the best diagnostic accuracy of all biomarkers assessed, the remaining markers still have different degrees of diagnostic accuracy in predicting the pCR rate in HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.